ATE333287T1 - Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten - Google Patents

Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Info

Publication number
ATE333287T1
ATE333287T1 AT99922536T AT99922536T ATE333287T1 AT E333287 T1 ATE333287 T1 AT E333287T1 AT 99922536 T AT99922536 T AT 99922536T AT 99922536 T AT99922536 T AT 99922536T AT E333287 T1 ATE333287 T1 AT E333287T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
demyelinating diseases
autoimmune demyelinating
fas
Prior art date
Application number
AT99922536T
Other languages
English (en)
Inventor
Takehiro Yatomi
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE333287T1 publication Critical patent/ATE333287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99922536T 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten ATE333287T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14953098 1998-05-29

Publications (1)

Publication Number Publication Date
ATE333287T1 true ATE333287T1 (de) 2006-08-15

Family

ID=15477161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922536T ATE333287T1 (de) 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Country Status (6)

Country Link
US (1) US6759041B1 (de)
EP (1) EP1082967B1 (de)
AT (1) ATE333287T1 (de)
CA (1) CA2333880A1 (de)
DE (1) DE69932434D1 (de)
WO (1) WO1999062554A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19959049A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
US7848848B2 (en) * 2006-04-28 2010-12-07 Freeslate, Inc. Robotic station for capturing both image and weight of a sample
US8771689B2 (en) 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
EP2104511A4 (de) 2006-12-11 2010-06-09 Univ Leland Stanford Junior Alpha-b-crystallin als therapie gegen entzündungen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230629A (ja) 1987-03-19 1988-09-27 Microbial Chem Res Found 自己免疫疾患予防治療剤
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
US6399327B1 (en) * 1995-07-16 2002-06-04 Yeda Research And Development Co. Ltd. Modulators of the function of FAS receptors and other proteins
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
DE69733773T2 (de) 1996-05-02 2006-04-20 Mochida Pharmaceutical Co. Ltd. Fas ANTIGEN-DERIVATE
CA2264968A1 (en) 1996-09-02 1998-03-12 Ko Okumura Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
EP1449539A2 (de) 1996-10-31 2004-08-25 Mochida Pharmaceutical Co., Ltd. Vorbeugende oder therapeutische Verwendung eines Fas-Antagonisten zur Inhibierung Fas-mediierten Apoptose
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
BR9814817A (pt) * 1997-10-10 2002-01-08 Cytovia Inc Inibidores de apoptose de dipeptìdio e o uso dos mesmos
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
EP1082967A4 (de) 2001-11-07
EP1082967B1 (de) 2006-07-19
DE69932434D1 (de) 2006-08-31
CA2333880A1 (en) 1999-12-09
EP1082967A1 (de) 2001-03-14
WO1999062554A1 (fr) 1999-12-09
US6759041B1 (en) 2004-07-06

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
EA200200208A1 (ru) Синергитическая композиция
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
PT705100E (pt) Guanidinas substituidas terapeuticas
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
DE69401577D1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69227696D1 (de) Zusammensetzungen zur behandlung von hiv-infektionen
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ATE333287T1 (de) Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties